Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,357 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06731413RecruitingPhase 2
Mild chemo with immunotherapy for older adults with advanced lung cancer
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
Richmond, VirginiaAges 18 years+ - NCT06731933RecruitingPhase 2
Gene therapy for skin cancer in recessive dystrophic epidermolysis bullosa
This trial tests a gene therapy called BVEC to see if it can prevent squamous cell carcinoma (a type of skin cancer) from coming back in people with a severe form of epidermolysis bullosa (fragile skin). It is for adults who have had a confirmed SCC and are willing to use the gene therapy.
Redwood City, CaliforniaAges 18 years+ - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT06735560Recruiting
PET scan with a tracer for liver, bile duct, or neuroendocrine tumors
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
NantesAges 18 years+ - NCT06736288RecruitingPhase 4
Buccalin® tablets to prevent repeat lung infections
This trial tests whether Buccalin® tablets can help adults who get frequent lower respiratory infections (like bronchitis or COPD flare-ups). It's a phase 4 study collecting more data on safety and how well the medicine works to prevent these infections from coming back.
AlessandriaAges 18–99 - NCT06742411RecruitingPhase 1/Phase 2
Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Chengdu, SichuanAges 18–75 - NCT06749860RecruitingPhase 2
Targeted drug combo for HER2-positive advanced lung cancer
This trial tests a combination of three drugs (Disitamab Vedotin, Tislelizumab, and Bevacizumab) for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene or protein. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT06754085RecruitingPhase 3
PET scan for suspected returning prostate cancer
This trial tests a new imaging drug, 18F-Florastamin, to see if it can better detect prostate cancer that has come back after treatment. You may qualify if you have signs of recurrence and are willing to have a biopsy or additional therapy.
GuangzhouAges 18 years+ - NCT06756334RecruitingEarly Phase 1
Comparing Two PET/CT Scans for Prostate Cancer
This study compares two types of PET/CT scans (using different radioactive tracers) to see which one is better at finding prostate cancer, detecting if it has come back, or spotting spread to other parts of the body. You will get both scans so doctors can compare them directly.
Hefei, AnhuiAges 18–90 - NCT06757153RecruitingEarly Phase 1
NRG-103 injection for recurrent glioblastoma patients
This trial tests an injection called NRG-103 given directly into the cavity where a recurrent brain tumor was removed. It is for people with glioblastoma that has come back and who have already had standard treatments.
Wuhan, HubeiAges 18 years+ - NCT06767254Recruiting
Using AI to predict early return of multiple myeloma
This study uses artificial intelligence to analyze how multiple myeloma may lead to early relapse. It may help doctors better predict and manage the disease.
Meldola, Forlì-CesenaAges 18 years+ - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT06776757RecruitingPhase 1/Phase 2
Sintilimab plus cetuximab and chemo for first-line advanced colorectal cancer
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
Shenzhen, GuangdongAges 18–75 - NCT06777017Recruiting
Can liver stiffness predict cancer return after ablation?
This trial studies if measuring liver and spleen stiffness can help predict the risk of liver cancer coming back after radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors. It aims to improve follow-up care for people with chronic liver disease and early-stage liver cancer.
BolognaAges 18 years+ - NCT06778603RecruitingPhase 1/Phase 2
Using B7-H3 imaging to guide osteosarcoma surgery
This trial tests a special dye that targets B7-H3, a protein found on osteosarcoma cells. Before your surgery, the dye is injected and helps surgeons see tumor edges more clearly, so they can remove all of the cancer while saving healthy tissue.
Beijing, Beijing MunicipalityAges 18–60 - NCT06781879RecruitingPhase 4
Comparing bladder medication vs surgery for returning low-grade bladder cancer
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
AalborgAges 18 years+ - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT06785415RecruitingPhase 1/Phase 2
Study of a drug combo for relapsed multiple myeloma
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Rochester, MinnesotaAges 18 years+ - NCT06790602RecruitingPhase 2
Cemiplimab plus gemcitabine for metastatic pancreatic cancer
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
La Jolla, CaliforniaAges 18 years+ - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06795009RecruitingPhase 1
Zanzalintinib plus paclitaxel for recurrent uterine cancer
This trial combines an experimental pill called zanzalintinib with a standard chemotherapy (paclitaxel) for people with advanced or recurrent high-grade uterine cancer who have already tried platinum-based chemotherapy. The goal is to see if this combination can help shrink or control the cancer better than standard options alone.
San Francisco, CaliforniaAges 18 years+ - NCT06795074RecruitingPhase 4
Comparing coated vs non-coated balloons for recurring urethral stricture
This trial tests if a balloon coated with a drug (paclitaxel) helps prevent the urethra from narrowing again after treatment. It may be an option for people whose stricture has come back after a prior procedure.
GothenburgAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,357 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.